18 August 2020: Clinical Research
Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
Ling Zhu 12ABCDEFG , Qianwei Cui 1BCEF , Ying Liu 3BCEF , Zhongwei Liu 1BCE , Yong Zhang 1BCF , Fuqiang Liu 1ACDEFG* , Junkui Wang 1ACDEFG*DOI: 10.12659/MSM.925114
Med Sci Monit 2020; 26:e925114
Figure 2 The cumulative incidence of major adverse cardiovascular events (MACEs) in the subgroup. (A) Patients in the cotherapy group showed a lower MACE occurrence than the beta-blocker monotherapy group (P=.004). (B) Patients in the cotherapy group showed a lower MACE occurrence than the statin monotherapy group (P=.022).